



Anti-Bacterial Drug Development:
Issues in the Design of Trials in Patients with
Unmet Need and in Patients with Hospital-
Acquired and Ventilator-Associated Bacterial
Pneumonia

Workshop Participant List

Sheraton Crystal City Hotel
1800 Jefferson Davis Highway Arlington, Virginia 22202
October 11 & 12, 2012

Jeff Alder

Senior Director,
Global Clinical Development Anti-Infectives
Bayer HealthCare

Paul Ambrose

President,
Institute for Clinical Pharmacodynamics and
Honorary Research Professor, University of
Oxford College of Medicine

Patrick Archdeacon (Teleconference)

Medical Officer,
Office of Medical Policy, CDER, FDA

John Bartlett

Professor of Medicine,
Johns Hopkins Center for Global Health
Infectious Diseases Society of America

Kimberly L. Bergman

Clinical Pharmacology Team Leader,
Anti-Infective Products, CDER, FDA

John Bradley

Professor and Chief,
Division of Infectious Diseases, Department of
Pediatrics, University of California, San Diego,
School of Medicine and Director, Division of
Infectious Diseases, Rady Children's Hospital
San Diego

Robert M. Califf

Vice Chancellor,
Clinical and Translational Research, Duke
University Medical Center and Director,
DTMI

Daniel Chertow

Staff Clinician,
Critical Care Medicine Department, Clinical
Center, NIH

Deborah Collyar

President,
Patient Advocates in Research

Heather M. Colvin

Senior Research Associate,
Engelberg Center for Health Care Reform,
The Brookings Institution

Edward Cox

Director,
Office of Antimicrobial Products, CDER, FDA

Aaron Dane

Infection Therapy Area Statistical Expert,
Research & Development, AstraZeneca

Robert Danner

Senior Investigator and Head,
Infectious Diseases Section, Critical Care
Medicine Department, NIH Clinical Center

Anita F. Das

Senior Vice President,
Biometrics, AxiStat, Inc.

John Farley (Teleconference)

Deputy Director,
Office of Antimicrobial Products, CDER, FDA

Thomas Fleming

Professor,
Department of Biostatistics, University of
Washington School of Public Health

Vance Fowler Jr.

Professor,
Department of Medicine, Infectious Diseases,
Duke University Medical Center

David Friedland

Vice President,
Clinical Sciences, Cerexa, Inc.

Cheryl Grandinetti (Teleconference)

Health Science Policy Analyst,
Office of Medical Policy, CDER, FDA

Robert Guidos

Vice President,
Public Policy & Government Relations,
Infectious Diseases Society of America

Alan Hopkins

Vice President,
Biometrics, Theravance, Inc.

Mohammad Huque

Director,
Division of Biometrics IV, Office of
Biostatistics, CDER, FDA

Dmitri Iarikov

Medical Officer,
Division of Anti-Infective Products, CDER,
FDA

John Jenkins

Director,
Office of New Drugs, CDER, FDA

Andre Kalil

Associate Professor of Medicine Director,
Transplant ID Program University of Nebraska

Michele Kennett

Director,
Human Research Protections,
University of Missouri Columbia

Charles Knirsch

Vice President,
Clinical Research Head, Specialty
Therapeutics, Pfizer Inc.

Judith Kramer

Professor of Medicine, Sr. Scientific Advisor,
Clinical Trials Transformation Initiative, DTMI,
Duke University Medical Center

Katherine Laessig

Deputy Director,
Division of Anti-Infective Products, CDER, FDA

Dante Landucci

Director,
Medical Allergy & Respiratory Center of
Excellence, Acute Care & Pain Network
General Medicine Therapeutic Delivery Unit
Quintiles

Joseph Larsen

Chief,
Broad Spectrum Antimicrobials Program,
Division of CBRN Medical Countermeasures,
Biomedical Advanced Research and
Development Authority

Lisa LaVange

Director,
Office of Biostatistics, CDER, FDA

Ben Lorenz

Medical Officer,
Division of Anti-Infective Products, CDER, FDA

Colonel Emil Lesho

Co-founder and Director,
Multidrug-resistant organism Repository and
Surveillance Network (MRSN) at Walter Reed
Army Institute of Research

Paula S. McKeever (teleconference)

Director,
Division of Medical Policy Development,
Office of Medical Policy, CDER, FDA

Kunal Merchant

Senior Clinical Project Manager,
Clinical Trials Transformation Initiative

Sumati Nambiar

Deputy Director for Safety,
Division of Anti-infective Products, CDER, FDA

Kathryn O'Connell

Medical Officer,
Rare Diseases Program, Office of New Drugs,
CDER, FDA

Kevin Outtersen

Associate Professor,
Boston University School of Law

John Powers

Senior Medical Scientist,
SAIC in support of Division of Clinical
Research, NIH and Associate Clinical Professor
of Medicine, George Washington University
School of Medicine

Philippe Prokocimer

Chief Medical Officer,
Trius Therapeutics, Inc.

Charlene Reed

Founder and Chief Executive Officer,
Foundation to Combat Antimicrobial Resistance

Kellie Reynolds

Deputy Division Director,
Division of Clinical Pharmacology IV, CDER,
FDA

Melissa Robb

Associate Director for Regulatory Affairs,
Office of Medical Policy Initiatives, CDER, FDA

John H. Rex

Vice President and Head of Infection,
Global Medicines Development, AstraZeneca
and Adjunct Professor of Medicine University of
Texas Medical School-Houston

Daniel Rubin

Biostatistician,
CDER, FDA

Leonard Sacks

Associate Director for Clinical Methodology,
Office of Medical Policy, CDER, FDA

Jonas Santiago

Analyst,
Division of Medical Policy Programs, CDER,
FDA

Rachel Sherman

Director,
Office of Medical Policy, CDER, FDA

Thomas Smith

Lead Medical Officer,
Division of Anti-Infective Products, CDER, FDA

Melissa Stundick

Project Officer
Broad Spectrum Antimicrobials Program
Division of CBRN Countermeasures, BARDA,
Office of the Assistant Secretary for
Preparedness and Response, DHHS

George H. Talbot

Principal,
Talbot Advisors LLC, Infectious Diseases
Society of America

Robert Temple

Deputy Center Director,
Clinical Science and Acting Deputy Director of
the Office of Drug Evaluation I, CDER, FDA

Rosemary Tiernan

Office of Medical Policy Initiatives
CDER, FDA

Joseph Toerner

Associate Director for Medical Affairs,
Office of Antimicrobial Products, CDER, FDA

John F. Tomayko

Senior Medical Director,
Infectious Diseases Therapeutic Area Unit,
GlaxoSmithKline

Ephraim L. Tsalik

Assistant Professor
Duke University Medical Center

Obiamiwe Umeh

Senior Director,
Clinical Research, Cubist Pharmaceuticals Inc.

Thamban Valappil

Statistician,
CDER, FDA

Christine Welch

Vice President,
Regulatory Affairs, Achaogen, Inc

David Wholley

Director,
Biomarkers Consortium, FNIH

Richard Wunderink

Professor of Medicine,
Pulmonary and Critical Care, Northwestern
University Feinberg School of Medicine